Therapeutic effect of dihydroartemisinin on Alzheimer’s disease model mice with senile macular degeneration by Gao Han, Gong Xuewu, Zhang Meng, Wang Yuejing, Wang Yuchun, Zhang Keshuang, Yao Hongbo

Subjects: Get full text

Serum lipids mediate the association of per- and polyfluoroalkyl substances exposure and age-related macular degeneration. by Xiaodong Chen, Jiaqi Li, Ningda Xu, Xuewei Li, Jiarui Li, Qianwen Guo, Jia Zhang, Heng Miao, Lvzhen Huang

“…<h4>Background</h4>This study aims to investigate the connection between serum lipids, per- and polyfluoroalkyl substances (PFAS), and age-related macular degeneration (AMD) risk and assess whether serum lipids mediate the association between PFAS and AMD.…”
Get full text

Modeling pegcetacoplan treatment effect for atrophic age-related macular degeneration with AI-based progression prediction by Irmela Mantel, Romina M. Lasagni Vitar, Sandro De Zanet

Subjects: “…Age-related macular degeneration…”
Get full text

A cross-tissue transcriptome-wide association study identified susceptibility genes for age-related macular degeneration by Hongfan Yang, Haofei Huang, Kunlin Pu

Subjects: Get full text

Abca4, mutated in Stargardt disease, is required for structural integrity of cone outer segments by John J. Willoughby, Abbie M. Jensen

Subjects: Get full text

Comparison of optical coherence tomography vs. fluorescein angiography-based macular neovascularization classifications in age-related macular degeneration by Gábor G. Deák, Klaudia Birner, Bianca S. Gerendas, Georgios Mylonas, Günther Weigert, Martin Michl, Irene Steiner, Ursula M. Schmidt-Erfurth

Get full text

Predictive value of different baseline optical coherence tomography biomarkers for visual acuity changes in neovascular age-related macular degeneration by Hamid Riazi-Esfahani, Hooshang Faghihi, Fatemeh Bazvand, Mohammadreza Mehrabi Bahar, Hassan Khojasteh, Ahmed Husein Ahmed, Shahin Faghihi, Ali Fakhraie, Mohammad Hossein Zamani, Samin Ghasemi, Esmaeil Asadi Khameneh, Elias Khalili Pour

Subjects: “…Age-related macular degeneration…”
Get full text

Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database by Tomohiro Iida, Aya Narimatsu, Kenji Adachi, Edward CY Wang

“…**Purpose:** To identify outpatient treatment patterns of patients with exudative age-related macular degeneration (AMD) who received approved anti–vascular endothelial growth factor (VEGF) therapy, using real-world data from hospitals in Japan. …”
Get full text

Lutein and inflammation: a comprehensive review of its mechanisms of action by Paradentavida Prathyusha, Geetha Viswanathan, Anjilikal Tomy Tomcy, Ponnamparambil P. Binitha, Smitha V. Bava, Edakkadath R. Sindhu

“…Additionally, it discusses lutein’s beneficial impact on macular degeneration and eye diseases, showcasing its potential as a natural, plant-based therapeutic agent.…”
Get full text

Dry eye disease treatment improves subjective quality-of-life responses in patients with AMD, independent of disease stage. by Nehal Nailesh Mehta, Ines D Nagel, Akshay Agnihotri, Anna Heinke, Lingyun Cheng, Dirk-Uwe Bartsch, William R Freeman, Maria-Laura Gomez

“…<h4>Purpose</h4>To determine the impact of severity of age-related macular degeneration (AMD) on subjective treatment response in patients treated for dry eye disease.…”
Get full text

Global, regional, and national burden of blindness and vision loss attributable to smoking from 1990 to 2021, and forecasts to 2030: findings from the Global Burden of Disease Stud... by Yi Zeng, Yixian Liu, Xingyi Chen, Jennifer Kenny, Rong Rong, Xiaobo Xia

“…Methods We extracted data on years lived with disability (YLDs) and age-standardized YLDs rate (ASYR) related to blindness and vision loss (BVL) caused by smoking, including cataracts and age-related macular degeneration (AMD), from the Global Burden of Disease (GBD) database for the years 1990 to 2021. …”
Get full text

Association of arterial stiffness and eye disease: a systematic review and meta-analysis by Robert Scragg, Angela L Beros, John D Sluyter

“…Background This systematic review and meta-analysis assesses the association of arterial stiffness with age-related macular degeneration (AMD), glaucoma, retinal vein occlusion (RVO) and retinopathy (diabetic and hypertensive).Methods Medline and Embase were systematically searched for observational studies of arterial stiffness and eye disease. …”
Get full text

Repeated exposure to low doses of light induces retinal damage in vivo in a wavelength-dependent manner by Anaïs Françon, Laurent Jonet, Francine Behar-Cohen, Alicia Torriglia

“…However, meta-analyses pointed out the role of lifelong light exposure in the onset of age-related macular degeneration, suggesting a cumulative effect of light exposure. …”
Get full text

The Association of Retinal Disease with Vision Impairment and Functional Status in Medicare Patients by Vincent Garmo, Xiaohui Zhao, Carmen D. Ng, Aimee Near, Tania Banerji, Keiko Wada, Gary Oderda, Diana Brixner, Joseph Biskupiak, Ferhina S. Ali, Archad M. Khanani, Alicia Menezes, Ibrahim M. Abbass

“…**Background:** The association of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) with functional status in the general Medicare population are not well established. …”
Get full text

Multi-omic spatial effects on high-resolution AI-derived retinal thickness by V. E. Jackson, Y. Wu, R. Bonelli, J. P. Owen, L. W. Scott, S. Farashi, Y. Kihara, M. L. Gantner, C. Egan, K. M. Williams, B. R. E. Ansell, A. Tufail, A. Y. Lee, M. Bahlo

“…The macula is disproportionately affected by high disease burden retinal disorders such as age-related macular degeneration and diabetic retinopathy, which both involve metabolic dysregulation. …”
Get full text

Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection by Ruamviboonsuk V, Kongwattananon W, Chuaypen N

“…Varis Ruamviboonsuk,1,2 Wijak Kongwattananon,1,3 Natthaya Chuaypen4 1Department of Ophthalmology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 2Medical Science Program, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 4Metabolic Diseases in Gut and Urinary System Research Unit (MeDGURU), Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandCorrespondence: Wijak Kongwattananon, Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873 Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand, Tel +662 256 4000, Email wijak.k@chula.ac.thPurpose: Intravitreal brolucizumab, approved for neovascular age-related macular degeneration (nAMD), may trigger immune responses leading to intraocular inflammation (IOI) by increasing pro-inflammatory cytokines. …”
Get full text

Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe by Barakat MR, Kwong Jr HM, Marcon G, O'Leary OE, Paris LP, Schneider P, Tang Y, Graff JM

“…., San Francisco, CA, USA; 6Barnet Dulaney Perkins Eye Center, Phoenix, AZ, USA; 7Ophthalmology Division, Creighton University School of Medicine, Phoenix, Arizona, USACorrespondence: Jordan M Graff, Barnet Dulaney Perkins Eye Center, Phoenix, AZ, USA, Tel +1 480 843 1868, Email JGraff@BDPEC.comPurpose: Faricimab, the first bispecific antibody designed for intraocular use, is approved for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). …”
Get full text

From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseases by Qing Zhao, Linxin Wei, Youxin Chen

“…To date, active trials include treatments for primary open angle glaucoma with MYOC mutations, refractory herpetic viral keratitis, CEP290-associated inherited retinal degenerations, neovascular age-related macular degeneration, and retinitis pigmentosa with RHO mutations. …”
Get full text

The effect of blue-blocking intraocular lenses on circadian biological rhythm: protocol for a randomised controlled trial (CLOCK-IOL colour study) by Taiji Hasegawa, Kenji Obayashi, Kimie Miyata, Tetsuo Ueda, Norio Kurumatani, Keigo Saeki, Nahoko Ogata, Hiroki Tsujinaka, Mariko Yamashita, Tomo Nishi, Nobuhiro Tone, Naonori Masuda, Yutarou Mizusawa, Masahiro Okamoto, Shinji Maruoka, Masashi Kojima, Toyoaki Matsuura

“…Meanwhile, blue light causes photochemical damage to the retina, and may be associated with age-related macular degeneration (AMD). At present, clear intraocular lenses (IOLs) and blue-blocking IOLs are both widely used for cataract surgery; there is currently a lack of randomised controlled trials to determine whether clear or blue-blocking IOLs should be used.Methods and analysis This randomised controlled trial will recruit 1000 cataract patients and randomly allocate them to receive clear IOLs or blue-blocking IOLs in a ratio of 1:1. …”
Get full text